98%
921
2 minutes
20
Retinoic acid (RA) signaling is a master regulator of vertebrate development with crucial roles in body axis orientation and tissue differentiation, including in the reproductive system. However, a mechanistic understanding of how RA signaling governs cell lineage identity is often missing. Here, leveraging prostate organoid technology, we show that RA signaling orchestrates the commitment of adult mouse prostate progenitors to glandular identity, epithelial barrier integrity, and specification of prostatic lumen. RA-dependent RARγ activation promotes the expression of Foxa1, which synergizes with the androgen pathway for luminal expansion, cytoarchitecture and function. FOXA1 mutations are common in prostate and breast cancers, though their pathogenic mechanism is incompletely understood. Combining functional genetics with structural modeling of FOXA1 folding and chromatin binding analyses, we discover that FOXA1 is a loss-of-function mutation compromising its transcriptional function and luminal fate commitment of prostate progenitors. Overall, we define RA as an instructive signal for glandular identity in adult prostate progenitors. Importantly, we identify cancer-associated FOXA1 indels affecting residue F254 as loss-of-function mutations promoting dedifferentiation of adult prostate progenitors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772605 | PMC |
http://dx.doi.org/10.1038/s44319-024-00335-y | DOI Listing |
Genes Dis
November 2025
Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, China.
Prostate cancer remains a major health problem, with its incidence ranking second among male malignancies worldwide. Recent studies have highlighted the critical role of the SOX family transcription factors, especially SOX2, in prostate cancer pathogenesis. SOX2 regulates the fate of cancer stem/progenitor cells, contributing to tumor initiation, development, and metastasis.
View Article and Find Full Text PDFFront Cell Dev Biol
July 2025
Faculty of Medicine, Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Introduction: Drug repurposing is gaining consideration in cancer due to the challenges of poor outcomes and resistance associated with the current conventional modalities. Non-steroidal anti-inflammatory drugs (NSAIDs), widely used for treating inflammation, are being explored for their potential efficacy in cancer treatment, including prostate cancer (PCa). This study aims to evaluate the efficacy of Piroxicam (PXM), an NSAID, in enhancing the sensitivity of PCa cells to chemotherapy and hormonal drugs.
View Article and Find Full Text PDFScience
September 2025
Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with inactivation, drive androgen-dependent adenocarcinomas through coactivation of mTORC1/2 and oncogenic AR signaling stemming from chimeric AR-half enhancers.
View Article and Find Full Text PDFMed Oncol
June 2025
Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, 400 056, India.
Perineural invasion (PNI) refers to the infiltration of tumor cells into the connective tissue of nerves and is increasingly recognized as a pathological hallmark of multiple cancers, including pancreatic, prostate, colorectal, breast, and head and neck malignancies. PNI is associated with aggressive tumor behavior, an increased risk of recurrence, and poor patient survival. This review consolidates current mechanistic insights into PNI, highlighting immune-neural crosstalk, Schwann cell activation, tumor-nerve feedback loops, and conserved neurotrophic signaling axes.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
July 2025
Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204.
Estrogen receptor β (ERβ) plays an important role in both the mouse and human prostate. The endogenous ligand for ERβ is the dihydrotestosterone metabolite, 5β-androstane-3β, 17β-diol (3β-Adiol). Thus, treatment with 5-α reductase inhibitor (5-ARI) should produce a phenotype similar to that seen in ERβ mice.
View Article and Find Full Text PDF